# Lenz Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/lenz-therapeutics

- Industry: Pharmaceuticals
- Headquarters: US
- Website: www.lenz-tx.com
- Total disclosed funding: $131M
- Latest round: Series B (Mar 6, 2023)
- Investors on record: 6

## About

Founded in 2013 and based in California, US, Lenz Therapeutics, Inc. develops an aceclidine-based eye drop that provides treatment for loss of near vision associated with presbyopia. The company was founded by Gerald Horn, M.D., Lee Nordan, M.D, and James McCollum. Mr. Eef Schimmelpennink serves as the CEO of Lenz Therapeutics. Mr. Schimmelpennink served as the former CEO of Alvotech, a pharmaceutical company. In June 2021, the company received its latest series A funding from a group of investors that includes Versant Ventures and RA Capital Management.

The company's product is an aceclidine-based eye drop that helps in restoring the vision of a person that was lost from a condition called Presbyopia. The solution targets the pinhole pupil located near the contracted iris muscles that will focus on the retina as a surrogate for accommodation.

The company's revenue is generated by the sales of the eye drops in the market specifically for persons that suffer from Presbyopia.

The company plans to enlist its aceclidine product towards an NDA submission.

## Funding rounds

- Series B, Mar 6, 2023, $84M — Versant Ventures, Alpha Wave Global, Sectoral Asset Management, RTW Investments, RA Capital Management, Point72 Asset Management
- Series A, Jun 17, 2021, $47M — Versant Ventures, RA Capital Management

## Investors

- Versant Ventures (https://capitalatlas.ai/funds/versant-ventures) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series A, Series B
- Alpha Wave Global (https://capitalatlas.ai/funds/alpha-wave-global) — Series B
- Sectoral Asset Management (https://capitalatlas.ai/funds/sectoral-asset-management) — Series B
- RTW Investments (https://capitalatlas.ai/funds/rtw-investments) — Series B
- Point72 Asset Management — Series B